Related Experiment Video

Updated: Jul 3, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

[Signal transduction by protein tyrosine kinases and antitumor agents]

Yong-Jun Mao1, Hai-Hong Li, Jian-Feng Li

  • 1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|July 31, 2008
PubMed

Insights

Signal transduction pathways are crucial for cell functions but overactivation drives tumor growth. This review covers key protein tyrosine kinase pathways and their targeted anticancer agents.

Area of Science:

  • Cellular biology
  • Molecular oncology
  • Biochemistry

Context:

  • Intracellular signal transduction regulates fundamental cellular processes including metabolism, differentiation, and cell death.
  • Aberrant signal transduction is a hallmark of cancer, driving tumor development and progression.
  • Protein tyrosine kinases (PTKs) are key regulators of these signaling pathways.

Purpose:

  • To provide a concise overview of critical intracellular signaling pathways regulated by protein tyrosine kinases (PTKs).
  • To highlight the role of these pathways in cancer.
  • To summarize current and emerging antitumor agents targeting these key signaling routes.

Summary:

  • This review focuses on five major signaling pathways: Ras/Raf/MAPK and PI-3K/Akt (mediated by receptor protein tyrosine kinases - RTKs), and Src, Bcr-Abl, and JAK/STAT (mediated by non-receptor protein tyrosine kinases - nrPTKs).
  • The intricate mechanisms of these pathways are briefly explained.
  • A summary of antitumor agents targeting pivotal proteins within these five pathways is presented.

Impact:

  • Enhances understanding of the molecular basis of cancer development.
  • Informs the development of targeted cancer therapies.
  • Provides a valuable resource for researchers and clinicians in oncology.

More Related Videos

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy12:24

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy

Published on: September 29, 2016

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...